Stand Up To Cancer returns on August 15. The biennial fundraising event is scheduled to occur in Nashville this year, which ...

The new platform integrates PCR-based diagnostic data with statistical modeling and AI to provide real-time visibility into ...

Updated label allows Neuraceq to be used in selecting patients for amyloid-targeting therapies and includes the use of ...

Pharmaceutical Executive: How is federal policy reshaping life sciences investments? John Stanford: Federal policy is ...

Due to popularity of the medications, GLP-1s were in short supply up until recently. Obesity is a common issue among ...

The supplemental premarket approval application is supported by Phase III data, which showed significant improvements in neck ...

Biljana Naumovic, US President, oncology, solid tumor, Johnson & Johnson Innovative Medicine, discusses the importance of ...

Jeff Liter, CEO of Luminary, discusses his company’s approach to CAR-T therapies and why the developing Saudi market has ...

Results from the Phase III VEGA-3 trial show that a significantly higher number of patients with presbyopia who received ...

The transaction, finalized following regulatory clearance, includes two FDA-approved rare tumor therapies: Ogsiveo for ...

Under terms of the deal, AbbVie will acquire Capstan’s lead asset, CPTX2309—an in vivo anti-CD19 CAR T-cell therapy in Phase ...

The recommendation for Enflonsia is indicated for respiratory syncytial virus prevention in infants under eight months of age ...